menu search

IMRA / What Makes IMARA Inc. (IMRA) a New Buy Stock

What Makes IMARA Inc. (IMRA) a New Buy Stock
IMARA Inc. (IMRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read More
Posted: May 19 2022, 13:33
Author Name: Zacks Investment Research
Views: 110613

IMRA News  

What Makes IMARA Inc. (IMRA) a New Buy Stock

By Zacks Investment Research
May 19, 2022

What Makes IMARA Inc. (IMRA) a New Buy Stock

IMARA Inc. (IMRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the more_horizontal

Read Why Imara Shares Are Falling Today

By Benzinga
April 5, 2022

Read Why Imara Shares Are Falling Today

Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (S more_horizontal

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 15, 2022

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript more_horizontal

Imara To Start Testing Tovinontrine In Heart Failure Patients

By Benzinga
January 25, 2022

Imara To Start Testing Tovinontrine In Heart Failure Patients

The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved more_horizontal

Imara To Start Testing Tovinontrine In Heart Failure Patients

By Benzinga
January 25, 2022

Imara To Start Testing Tovinontrine In Heart Failure Patients

The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved more_horizontal

Imara To Start Testing Tovinontrine In Heart Failure Patients

By Benzinga
January 25, 2022

Imara To Start Testing Tovinontrine In Heart Failure Patients

The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved more_horizontal


Search within

Pages Search Results: